Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder.
Gilad FainbergYael LeitnerDinah ZurAinat KleinDaphna Mezad-KourshPublished in: Journal of child and adolescent psychopharmacology (2022)
Objective: To evaluate the short-term effect of dexmethylphenidate (D-MPH) on visual acuity (VA), pupil size, anterior chamber depth, and accommodation-convergence reflex in children treated with D-MPH for attention-deficit/hyperactivity disorder (ADHD). Method: Prospective cohort study including 15 patients aged 8-16 (11.58 ± 2.39) treated with D-MPH for ADHD. Patients were questioned for subjective complaints such as blurred vision and photosensitivity. An ophthalmic evaluation was performed twice; before and 1.5 hours after D-MPH administration. The examination included evaluation of best corrected visual acuity at distance and near, accommodation range, convergence range, 3D vision test (stereopsis), and anterior segment optical coherence tomography. Results: A significant association between change in pupil diameter and D-MPH treatment dose was demonstrated ( p = 0.01). In addition, a positive correlation between complaints about blurred vision and pupil's size change was found ( p < 0.05). There were no significant changes in VA, convergence range, stereopsis, accommodation range, or anterior chamber measures. Conclusions: Our findings provide support for the effect of stimulants on pupil diameter in a dose-dependent manner. No clinically significant differences in visual functions were found 1.5 hours after consumption of D-MPH. Institutional review board clinical trial refference no. 0122-17-TLV.
Keyphrases
- attention deficit hyperactivity disorder
- autism spectrum disorder
- end stage renal disease
- newly diagnosed
- clinical trial
- working memory
- optical coherence tomography
- ejection fraction
- chronic kidney disease
- prognostic factors
- optic nerve
- young adults
- physical activity
- open label
- randomized controlled trial
- patient reported outcomes
- combination therapy
- replacement therapy
- sleep quality
- drug induced